| Document |
Document Title |
|
WO/2019/063069A1 |
The invention relates to the use of a compound of formula (I) as described herein as an aromatic substance. The invention also relates to novel compounds of formula (I) as described herein or mixtures comprising at least one different co...
|
|
WO/2019/024339A1 |
A photosensitizer and derivatives and an application thereof. The photosensitizer has the structure of general formula I, X is S or Se, Y is an organic or inorganic ion, R1 and R2 are respectively independently selected from H, alkyl, al...
|
|
WO/2019/008141A1 |
The present invention provides a phenothiazine derivative of formula (I) for use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as N.meningitidis,and more specifically for use in preventing and/or ...
|
|
WO/2018/234805A1 |
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
|
|
WO/2018/232675A1 |
Methylene blue (MB) derivatives selectively detect F-by desilylation reaction to act as a fluorescent probe.
|
|
WO/2018/167185A1 |
The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5- ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(dimethylamino)-phenothiazin-...
|
|
WO/2018/159459A1 |
Provided is a diarylamine-based compound represented by a general formula (1) (in general formula (1), A1 and A2 each independently represent an arylene group which has 6-18 carbon atoms and may have a substituent, and A3 and A4 each ind...
|
|
WO/2018/158520A1 |
Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide, the method resulting in a high purity while being very simple to implement and producing high yields. The method uses phenothiazine as a starting material and compri...
|
|
WO/2018/156429A1 |
Lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P), other lanthionine ketimine, lanthionine ketimine phosphonate, and lanthionine ketimine ester derivatives, and methods of making and using the same, ...
|
|
WO/2018/152436A1 |
The present invention provides novel phenazine derivatives, such as compounds of Formula (I) (e.g., Formulae (II) - (XIX)), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be antimicrobial ag...
|
|
WO/2018/126107A1 |
The present disclosure provides methods and compositions for the treatment of oral lesions in a subject comprising a methylene blue oral rinse.
|
|
WO/2018/121267A1 |
A [1,3]thiazol-2-amine compound, an application, and a pharmaceutical composition. The present invention belongs to the field of BACE inhibitors. The [1,3]thiazol-2-amine compound is a compound represented by formula (I), or a pharmaceut...
|
|
WO/2018/115292A1 |
The present invention pertains generally to the field of chemical synthesis, and more particularly to methods for the chemical synthesis of a thiosulfonic acid of Formula (1) by a step of periodate mediated oxidative coupling of a thiosu...
|
|
WO/2018/112086A1 |
The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I) wherein variables A, R1, R2, R2', R3, R4, and R5 of Formula (I) are def...
|
|
WO/2018/075533A1 |
An electrochromic device includes a compound of Formula (I): wherein. R1 and R2 are individually alkyl, alkoxy, or aryloxy; R3, R4, R5, R6, R7, R8 are individually H, alkoxy, or aryloxy; R9 and R10 are individually alkoxy, or aryloxy, or...
|
|
WO/2018/075172A1 |
The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such comp...
|
|
WO/2018/051278A2 |
The present invention relates to a compound of formula (I) based on enamine derivatives and used as organic hole conductors or hole transporting material in an optoelectronic or photoelectrochemical device. The present invention relates ...
|
|
WO/2018/039487A1 |
The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R1, R2, R3, R4, subscipt m and n, have the meaning as described herein, and compositions containing such ...
|
|
WO/2018/020974A1 |
Provided are the following: a sulfonium salt which does not contain a toxic metal and which exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt; a heat- or photo-...
|
|
WO/2017/222466A1 |
The present invention relates to heterocyclic compounds of Formula I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compo...
|
|
WO/2017/216299A1 |
The object of the present invention are compounds comprising at least one donor group and at least one acceptor group, as described herein, which are characterized by a pronounced CT character. The invention also relates to the use there...
|
|
WO/2017/215549A1 |
Disclosed are an organic electroluminescent compound and an application thereof. The structural formula of the compound is as shown in general formula (1). The material has good fluorescence quantum efficiency and electroluminescence eff...
|
|
WO/2017/199162A1 |
A process for the preparation of diaminophenothiazinium compounds is described, which allows achieving quickly and effectively a high degree of purity of the same.
|
|
WO/2017/200354A1 |
Disclosed are an oxime ester derivative compound, a photopolymerization initiator comprising the same, and a photosensitive composition.
|
|
WO/2017/147440A1 |
Lanthionine ketimine derivatives, and methods of making and using the same, are described. Included are lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P) derivatives, as well as lanthionine ketimine ...
|
|
WO/2017/116903A1 |
Disclosed herein are methods for preparing ultrapure diaminophenothiasinium compounds with high solubility in solutions, e.g., water, and the compositions provided therefrom.
|
|
WO/2017/114857A1 |
The invention relates to compounds, comprising at least one donor group and at least one acceptor group, in which the transition energy of the lowest excited triplet back into the ground state both of the corresponding donor molecule and...
|
|
WO/2017/108152A1 |
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.
|
|
WO/2017/111042A1 |
The present invention provides a process for preparation of the compound of formula (VI), wherein each symbol is as defined in the specification, without using any intermediate compound showing mutagenicity. The process comprises salt fo...
|
|
WO/2017/100882A1 |
This invention patent relates, in a first aspect, to cell staining compositions comprising a mixture of dyes or salts and complexes thereof in an aqueous medium and optionally a cell lysis agent. Also disclosed are methods for preparing ...
|
|
WO/2017/102063A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2017/104589A1 |
Provided is a method for producing a perfluoroalkylated compound at low cost, safely and with high efficiency. A method for producing a perfluoroalkylated compound, comprising reacting a bis(perfluoroalkanoyl)peroxide with a compound tha...
|
|
WO/2017/100869A1 |
This invention patent relates, in a first aspect, to cell staining compositions comprising a mixture of dyes or salts and complexes thereof in an aqueous medium and, optionally a cell lysis agent. Also disclosed are methods for preparing...
|
|
WO/2017/078927A1 |
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...
|
|
WO/2017/070718A1 |
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...
|
|
WO/2017/051355A1 |
The present invention relates to compounds characterized by having a structure according to the following Formula (I), or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prev...
|
|
WO/2017/045750A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as ASIC inhibitors.
|
|
WO/2017/044571A1 |
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...
|
|
WO/2017/040965A1 |
A lubricant composition includes a base oil present in an amount of greater than 70 parts by weight per 100 parts by weight of the lubricant composition and an antioxidant. The antioxidant has the structure: wherein each X is independent...
|
|
WO/2017/040963A1 |
The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2', L, X, W, Y1,Y2, Y3, and Y4 are described herein.
|
|
WO/2017/027829A1 |
Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of ce...
|
|
WO/2017/024180A1 |
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 a...
|
|
WO/2017/013174A1 |
The present invention pertains generally to the field of chemical synthesis, and more particularly to methods of chemical synthesis which include the step of preparing a substituted 10H-phenothiazine-3,7-diamine compound of Formula (1) b...
|
|
WO/2017/005668A1 |
Compounds of the formula I: or a pharmaceutical salt thereof, wherein p, s, A, R3 and Re are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as art...
|
|
WO/2017/000869A1 |
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...
|
|
WO/2016/197730A1 |
The present invention relates to an organic electroluminescent material, which has a structure as represented by formula (I). Compounds as represented by formula (I) have highly stable electron acceptor groups and electron donor groups, ...
|
|
WO/2016/201225A1 |
The invention provides aryl dihydro-2H-benzo[b] [l,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treat...
|
|
WO/2016/198937A1 |
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds...
|
|
WO/2016/173020A1 |
A conjugated compound containing a diphenyl sulfone phenyl structure, a method for preparing same, and use for fabricating a light emitting layer or an electronic transmission layer of an organic electroluminescent diode. The compound ha...
|
|
WO/2016/151011A1 |
2-homopiperazine-1-yl-4H-l, 3 -bensothiazine-4-one derivatives of formula (I) are provided. They are useful in the treatment of bacterial infections, in particular tuberculosis, buruli ulcer and leprosy. A process for the preparation of ...
|
